BR112018004078A2 - composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo - Google Patents
composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduoInfo
- Publication number
- BR112018004078A2 BR112018004078A2 BR112018004078-9A BR112018004078A BR112018004078A2 BR 112018004078 A2 BR112018004078 A2 BR 112018004078A2 BR 112018004078 A BR112018004078 A BR 112018004078A BR 112018004078 A2 BR112018004078 A2 BR 112018004078A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treating cancer
- fusion protein
- individual
- agent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010027476 Metastases Diseases 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 abstract 2
- 230000036952 cancer formation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002137 anti-vascular effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
the present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-vegf) agent are fused, for treating cancer or angiogenesis-related diseases. more specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-vegf agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0123878 | 2015-09-01 | ||
KR20150123878 | 2015-09-01 | ||
PCT/KR2016/009801 WO2017039358A1 (ko) | 2015-09-01 | 2016-09-01 | 종양 투과성 펩타이드와 향-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018004078A2 true BR112018004078A2 (pt) | 2018-12-11 |
Family
ID=58188859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018004078-9A BR112018004078A2 (pt) | 2015-09-01 | 2016-09-01 | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo |
Country Status (15)
Country | Link |
---|---|
US (1) | US10919947B2 (pt) |
EP (1) | EP3345613B1 (pt) |
JP (1) | JP6893928B2 (pt) |
KR (1) | KR102128966B1 (pt) |
CN (1) | CN108348575B (pt) |
AU (1) | AU2016317882B2 (pt) |
BR (1) | BR112018004078A2 (pt) |
CA (1) | CA2996937C (pt) |
DK (1) | DK3345613T5 (pt) |
ES (1) | ES2951260T3 (pt) |
FI (1) | FI3345613T3 (pt) |
MX (1) | MX2018002524A (pt) |
RU (1) | RU2727238C2 (pt) |
SI (1) | SI3345613T1 (pt) |
WO (1) | WO2017039358A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
KR101948238B1 (ko) | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
US20200165312A1 (en) * | 2017-06-28 | 2020-05-28 | Lg Household & Health Care Ltd. | Cosmetic composition for improving skin conditions comprising fusion protein including skin penetration enhancing peptide |
AU2018304957A1 (en) * | 2017-07-18 | 2020-02-13 | In3Bio Ltd | Synthetic proteins and therapeutic uses thereof |
CA3075403A1 (en) * | 2017-09-08 | 2019-03-14 | Ajou University Industry-Academic Cooperation Foundation | Composition for restraining activity of regulatory t cell, comprising peptide binding specifically to neuropilin 1 (nrp1) |
US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
CN113164544A (zh) * | 2018-10-12 | 2021-07-23 | 三钰生物科技股份有限公司 | 双功能性融合蛋白及其用途 |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
CN112522322A (zh) * | 2020-12-24 | 2021-03-19 | 深圳市人民医院 | 一种nrp1配体的修饰技术 |
CN114028541A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | Gdf2在制备改善肿瘤异常血管的药物中的用途 |
WO2023134787A2 (zh) * | 2022-01-14 | 2023-07-20 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
KR102459219B1 (ko) * | 2022-03-31 | 2022-10-26 | 주식회사 셀아이콘랩 | 신규한 피부투과성 펩타이드, 이를 포함하는 피부 및 점막 조성물과 이의 용도 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
RU2008106230A (ru) * | 2005-07-19 | 2009-08-27 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования |
MX2009012968A (es) | 2007-06-06 | 2010-04-01 | Domantis Ltd | Polipeptidos, dominios variables de anticuerpo y antagonistas. |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
CA2766634A1 (en) * | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
EP4306123A3 (en) * | 2011-12-22 | 2024-04-17 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
US9116159B2 (en) * | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
WO2014189303A1 (ko) * | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
KR101551306B1 (ko) * | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
-
2016
- 2016-09-01 KR KR1020160112699A patent/KR102128966B1/ko active IP Right Grant
- 2016-09-01 WO PCT/KR2016/009801 patent/WO2017039358A1/ko active Application Filing
- 2016-09-01 SI SI201631730T patent/SI3345613T1/sl unknown
- 2016-09-01 MX MX2018002524A patent/MX2018002524A/es unknown
- 2016-09-01 CN CN201680060604.2A patent/CN108348575B/zh active Active
- 2016-09-01 BR BR112018004078-9A patent/BR112018004078A2/pt active Search and Examination
- 2016-09-01 FI FIEP16842324.2T patent/FI3345613T3/fi active
- 2016-09-01 AU AU2016317882A patent/AU2016317882B2/en active Active
- 2016-09-01 JP JP2018530461A patent/JP6893928B2/ja active Active
- 2016-09-01 CA CA2996937A patent/CA2996937C/en active Active
- 2016-09-01 ES ES16842324T patent/ES2951260T3/es active Active
- 2016-09-01 EP EP16842324.2A patent/EP3345613B1/en active Active
- 2016-09-01 RU RU2018111390A patent/RU2727238C2/ru active
- 2016-09-01 DK DK16842324.2T patent/DK3345613T5/da active
-
2018
- 2018-03-01 US US15/909,086 patent/US10919947B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3345613A1 (en) | 2018-07-11 |
EP3345613A4 (en) | 2019-08-14 |
US20180237484A1 (en) | 2018-08-23 |
KR20170027312A (ko) | 2017-03-09 |
CN108348575A (zh) | 2018-07-31 |
RU2018111390A3 (pt) | 2020-01-31 |
CA2996937C (en) | 2024-02-06 |
ES2951260T3 (es) | 2023-10-19 |
CA2996937A1 (en) | 2017-03-09 |
CN108348575B (zh) | 2022-06-14 |
AU2016317882B2 (en) | 2021-01-28 |
RU2727238C2 (ru) | 2020-07-21 |
EP3345613B1 (en) | 2023-05-10 |
US10919947B2 (en) | 2021-02-16 |
JP6893928B2 (ja) | 2021-06-23 |
JP2018531989A (ja) | 2018-11-01 |
FI3345613T3 (fi) | 2023-07-28 |
RU2018111390A (ru) | 2019-10-04 |
SI3345613T1 (sl) | 2023-10-30 |
DK3345613T5 (da) | 2024-09-30 |
AU2016317882A1 (en) | 2018-04-19 |
DK3345613T3 (da) | 2023-07-31 |
WO2017039358A1 (ko) | 2017-03-09 |
MX2018002524A (es) | 2018-11-09 |
KR102128966B1 (ko) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018004078A2 (pt) | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo | |
EA201890456A1 (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
EA201792047A1 (ru) | Новые соединения | |
BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
EA201491644A1 (ru) | Фармацевтические композиции | |
PE20181159A1 (es) | Proteinas de fusion para tratar trastornos metabolicos | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
EA201690159A1 (ru) | Способы и композиции для лечения рака | |
PE20170142A1 (es) | Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
MX2015011846A (es) | Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades. | |
PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |